The compounds were tested against T. b. rhodesiense and P. falciparum.
Introduction
Human African trypanosomiasis (HAT) and malaria are parasitic diseases that are endemic in sub-Saharian Africa where they cause great morbidity and high mortality rates (especially for malaria). Two subspecies of trypanosomes (Trypanosoma brucei gambiense and T. b. rhodesiense) lead to chronic and acute forms of HAT, respectively [1] . The apicomplexan parasite Plasmodium falciparum, which is the cause of the most severe and deadly form of malaria, is mainly prelavent in Africa being responsible of over 75% of cases in that continent [2] .
New drugs are required to complete and/or improve the chemotherapeutic arsenal available for both diseases. On the one hand, drugs for the treatment of HAT are scarce (i.e. pentamidine, suramin, melarsoprol, eflornithine and nifurtimox-eflornithine combination therapy -NECT -), stage and species specific, very toxic, and not orally active [3, 4] . On the other hand, malaria chemotherapy is suffering from extended resistance to conventional drugs (e.g. chloroquine) and the rapid development of Plasmodium strains that are resistant to "newly" marketed drugs (e.g. artemisinin) [5, 6] . In a word, new drugs are urgently needed to fight against these deadly diseases.
Dicationic compounds such as diamidines [7] [8] [9] [10] and bis(2-aminoimidazolines) [11] [12] [13] have a track record of success as antiprotozoan agents. These compounds bind strongly to the DNA minor groove at AT-rich sites which is one of the known targets of these molecules. Accordingly dicationic diamidines were shown to be localized to the DNAcontaining nucleus and/or kinetoplast of trypanosomes [14] . Bisguanidine related molecules are also very active against T. brucei and P. falciparum [11] [12] [13] [15] [16] [17] [18] [19] .
However, low nanomolar in vitro activities do not always result in potent in vivo activity in murine models of HAT and malaria [16, 17] . Besides, this class of dibasic compounds is highly polar (i.e. dicationic at physiological pH) and, like pentamidine, mostly fails in curing CNS-stage T. brucei infections.
In recent years, we have discovered a set of bisguanidinium hits that displayed excellent activities in vitro against T. b. rhodesiense and P. falciparum [11] . Two hit compounds derived from the N-phenylbenzamide scaffold (I) and the 1,3-diphenylurea scaffold (II)
that presented nanomolar IC 50 s, adequate selectivities, and promising in vivo activity in the STIB900 mouse model of acute HAT were chosen as templates for further development ( Figure 1 ). The choice of these scaffolds as antitrypanosomal templates was also supported by the excellent results obtained with bis (2-aminoimidazoline) analogues that proved to be 100% curative in vivo in the STIB900 mouse model [11] . (I) and 1,3-Diphenylurea (II) Bisguanidinium Leads [11] In previous work, Arafa et al [15] showed that N-alkyl derivatives of diguanidino fused ring systems had improved in vivo potency in the STIB900 mouse model of acute HAT compared with the unsubstituted diguanidino parent compounds. In the present study, we tested a similar strategy with the hits I and II to check if the antiprotozoan activity of these hits could be enhanced in that way. In fact, the addition of N-alkyl and Nalkoxy substituents in the structure should increase the lipophilicity of the compounds whereas N-alkoxy substituents should decrease their basicity with respect to I and II.
All of these modifications were expected to enhance the antiprotozoan activity of the compounds as well as to improve their membrane permeation (e.g. blood-brain barrier).
Hence, six N-alkyl (7a-c, 8a-c), four N-alkoxy (7d-g), and one hydroxy derivatives of the hits I and II were synthesised and tested against T. b. rhodesiense and P.
falciparum. The most active compounds in vitro were further evaluated in vivo in the STIB900 mouse model of acute HAT. This allowed drawing preliminary structureactivity relationships (SAR) for antimalarial and antitrypanosomal activity. Besides, the DNA binding affinity of the compounds was assessed by surface plasmon resonance (SPR) biosensor experiments with three different hairpin oligonucleotides.
Results

Chemistry
N-substituted guanidines 7a-g and 8a-c were synthesized in three steps from diamines 1 and 2, respectively, following the Manimala and Anslyns's methodology (Scheme 1) [20] . The synthesis started with the preparation of the bis(ethoxycarbonylthioureas 3 and 4 from 4-amino-N-(4-aminophenyl)benzamide and 1,3-bis(4-aminophenyl)urea, respectively. These thioureas were reacted with an excess (4 equiv.) of N-alkyl (R = Me, Et, i Pr) and N-alkoxy amines (R = OMe, OEt, OBn, OTHP) in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC) and N,N-diisopropylethylamine and 6a-c. Two strategies were tried to remove the ethoxycarbonyl groups to obtain the target guanidines 7a-h and 8a-c.
Scheme 1.
a Synthesis of N-alkyl and N-alkoxy guanidines
5a: X = NHCO; R = Me (64%) 5b: X = NHCO; R = Et (82%) 5c: X = NHCO; R = i Pr (77%) 5d: X = NHCO; R = OMe (43%) 5e: X = NHCO; R = OEt (55%) 5f: X = NHCO; R = OBn (70%) 5g: X = NHCO; R = OTHP (60%) 6a: X = NHCONH; R = Me (67%) 6b: X = NHCONH; R = Et (60%) 6c: X = NHCONH; R = i Pr (67%)
iii, iv iv 7a: X = NHCO; R = Me (94%)* 7b: X = NHCO; R = Et (81%) 7c: X = NHCO; R = i Pr (71%) 7d: X = NHCO; R = OMe (69%) 7e: X = NHCO; R = OEt (85%) 7f: X = NHCO; R = OBn (95%) 7g: X = NHCO; R = OTHP (85%) 7h: X = NHCO; R = OH (69%) 8a: X = NHCONH; R = Me (81%) 8b: X = NHCONH; R = Et (91%) 8c: X = NHCONH; R = i Pr (71%)
. The first strategy using Lewis acids such as trimethylsilyl (TMSCl) chloride [21, 22] and bromide (TMSBr) [20] to generate directly the guanidinium salts was mostly unsuccessful in our hands, leading to complex mixtures of partially and fully deprotected products together with 2-alkylamino(3H)quinazolin-4-one by-products as previously reported [22] . Apparently, the success of this deprotection protocol is very dependent on the R group present on the guanidine moiety [e.g. compound 5c with R = i Pr was cleanly deprotected using TMSCl (10 equiv) / DMF / 80 ºC / MW / 60 min] and was not applicable to most of our compounds. Optimal conditions for the removal of the ethoxycarbonyl groups took place under basic conditions (0.1 M aqueous KOH in
MeOH at 80 ºC in a sealed tube) to yield 7a-g and 8a-c as free bases. Hydrochloride salts of 7a-f, 8a-c, and 7h [23] were obtained from the free base guanidines 7a-f, 8a-c, and 7g with HCl gas -saturated 1,4-dioxane solution, respectively.
In Vitro and In Vivo Antiprotozoal Activity
The target compounds 7a-h and 8a-c were tested in vitro against T. brucei rhodesiense (STIB900 strain) by means of an Alamar blue-based assay [24] . The antimalarial activity against erythrocytic forms of P. falciparum was evaluated with a [ 3 H]hypoxanthine incorporation assay [25] using the chloroquine-sensitive strain NF54.
The cytotoxicity of the compounds against mammalian L6-cells was also evaluated to determine their selectivity index. The results are shown in Table 1 .
All of the guanidines with N-alkyl substituents (7a-c and 8a-c) displayed submicromolar range IC 50 values against T. b. rhodesiense. Compounds with ethyl (7b, 8b) and isopropyl groups (7c, 8c) were particularly effective with low nanomolar IC 50
values, in the range of the reference drug melarsorprol (IC 50 = 8 nM), and high selectivities (SI > 1000). These values represent a 2-to 3-fold increase in antitrypanosomal activity compared with the unsubstituted parent compounds II and I, respectively. In contrast, N-hydroxy (7h) and N-alkoxy (7d, 7g) guanidines showed weak activity. As far as the linker of the diphenyl scaffold is concerned, the amide gave 5-to 10-fold higher potencies than the urea linker. In general, most of these guanidines presented low cytotoxicity (IC 50 > 100 µM against L6-cells) even though some differences could be observed between both series. Compound I derivatives (7a-d and 7g-h) in particular were approximately 10-times less cytotoxic than the parent guanidine I. On the contrary, derivatives 8a-c were somewhat more cytotoxic than II.
As with the anti-T. brucei activity, the best antimalarial compounds were the N-alkyl To evaluate the in vivo potential of these new N-alkyl guanidines, the best trypanocidal compounds in vitro (7b, 7c, 8b, and 8c) were tested in a mouse model of acute (stage 1)
HAT. Groups of four mice infected with T. b. rhodesiense (strain STIB900) received a four days treatment (days 3, 4, 5 and 6 post-infection) with the tested compounds (4×20 mg/kg ip). One control group (3 mice) remained untreated. The blood parasitemia was checked periodically over the 60 days of the experiment and the mean day of relapse of parasitemia was calculated. The mice that survived 60 days free of parasites were considered as cured ( Table 1 ). 4 ] immobilized on a chip biosensor surface [30, 31] . All of the compounds were first screened for binding to the three oligonucleotide sequences at a single concentration (25 µM) . This allowed the ranking of the compounds as binders/non binders (data not shown). Then, the binding constants of the most interesting compounds with the three different DNA hairpins were determined ( Table   2) Hence, in this series, the alkylation of the guanidine moieties resulted in a decrease in binding affinity to AT sequences. Besides, no important differences in binding were observed between i Pr and Et groups. These findings agree with the data reported earlier with a series of linear triaryl bisguanidines [17] .
On the one hand, none of the compounds tested bound significantly to the (CG) 4 sequence ( Figure 2B ) suggesting a specific AT-rich minor groove mode of binding for 7b and 7c. On the other hand, binding of the urea derivative 8b was approximately 30-times weaker than that of 7b and 7c (K < 1× 10 5 M -1 ) suggesting unspecific binding to DNA. 5'-biotin labelled DNA sequences used (the hairpin loop is underlined):
Taken from reference [26] . 
Discussion
Two series of N-substituted bisguanidines derived from the N-phenylbenzamide and the 1,3-diphenylurea scaffolds (7a-h and 8a-c, respectively) were synthesized and evaluated as antitrypanosomal and antimalarial agents. The aim of this research was to improve the antiprotozoal activity of the leads I and II by introducing N-alkyl and N-alkoxy substituents on the guanidine moieties. As far as T. brucei is concerned, this was achieved successfully with the introduction of Et and i Pr substituents to get low nanomolar range IC 50 s (7b and 7c, respectively). A similar effect, although less pronounced, was obtained with the 1,3-diphenylurea derivatives 8b and 8c.
Interestingly, the trypanocidal activity enhancement effect due to alkyl substitution was dependant on the size of the alkyl group. Hence, methyl groups were detrimental to the activity (e.g. compare 7a vs. I and 8a vs. II) whereas the larger isopropyl substituent gave lower IC 50 values in comparison with the leads. These results indicate that, in this series, big and/or lipophilic alkyl substituents are favourable for antitrypanosomal activity ( Figure 3 ). Remarkably, these SAR results are opposite to the findings reported by Arafa et al with a series of linear triaryl bisguanidines [17] . In contrast, small alkyl groups appeared to be favourable to increase the antimalarial activity of the urea (Me > Et > i Pr) and the benzamide (Et > i Pr) derivatives as previously reported [17] . The introduction of alkoxy substituents on the guanidine groups (7d, 7f, 7g) was detrimental to both antitrypanosomal and antimalarial activities although N-hydroxy substituents were somewhat better tolerated (IC 50 < 5 µM). These results are consistent with those observed for fused ring bisguanidines [15] . In general, the difference in SAR between antitrypanosomal and antimalarial action probably reflects the presence of different cellular targets for both antiparasitic activities ( Figure 3 ).
The excellent in vivo efficacy of 7b and 7c in the mouse model of first stage HAT is linked to favourable drug-like properties (i.e. bioavailability, lead likeness, Lipinski rule of 5) as observed with I ( Table 3 ). Considering that compound I was 100% curative by oral dosage in this mouse model, further in vivo studies with 7b and 7c are clearly warranted. In contrast, urea derivatives 8b and 8c were weakly active in the STIB900 model and showed acute toxicity issues in vivo. This was somewhat unexpected as both compounds displayed low cytotoxicity against rat L6-cells (> 100 µM) resulting in high selectivity indices in vitro (SI > 1200). However, the drug-like properties calculated for 8b and 8c are clearly less than optimum (Table 3 ) and may explain the poor efficacy of these compounds in vivo.
Among the new compounds reported here, two molecules derived from the Nphenylbenzamide scaffold, 7b and 7c, bound strongly to AT-rich DNA. No correlation between DNA binding and in vitro activity was observed which was not unexpected as this is a general trend that has been reported previously with related bisguanidines and other dicationic minor groove binders [11] . However, it was also noted in these reports that weak DNA binding results in reduced antitrypanosomal activity [15, 29, 32, 33] .
Hence, the level of DNA binding displayed by 7b and 7c is consistent with the existence of a DNA target (even though this may not be the sole target). 
Conclusions
In this study we have shown that the N-alkylation of the guanidine moiety is an effective strategy to enhance the antiparasitic activity of leads I and II against T. b.
rhodesiense, whilst it is detrimental to the antimalarial action and DNA binding affinity.
Low nanomolar IC 50 values against T. b. rhodesiense were obtained with ethyl and isopropyl substituents (7b, 7c, 8b, and 8c). However, only 7b and 7c showed in vivo efficacy (100% cures) in the STIB900 mouse model of acute HAT. Hence, N-alkylated bisguanidines derived from the N-phenylbenzamide scaffold are very promising DNA binders with in vivo antitrypanosomal activities that outperform the triaryl class of bisguanidines [16, 17] . Because of their favourable drug-like properties, further studies of these molecules are warranted.
Interestingly, several SAR differences against T. brucei were observed (i.e. guanidine Q-TOF 6520 spectrometer using electrospray ionization.
General procedure for the synthesis of bis(ethoxycarbonylthioureas) (3, 4)
To a solution of diamine 1 or 2 (1 equiv.) in dry CH 2 Cl 2 (15 mL) cooled to 0 ºC and under argon atmosphere, was added slowly an excess of ethoxycarbonyl isothiocyanate (2.2 equiv.). The reaction mixture was stirred at room temperature overnight and the precipitate was collected by filtration. The precipitate was rinsed with hexane to yield the ethoxycarbonylthioureas 3 and 4 with good yields. washed successively with water (3 × 10 mL) and brine (10 mL). The organic phase was dried (MgSO 4 ) and the solvent evaporated under vacuum. The product was purified as specified in each case.
4-(3-Ethoxycarbonyl-2-methylguanidino)-N-(4-(3-ethoxycarbonyl-2-methylguanidino)phenyl)benzamide (5a)
Compound 5a was obtained following the general procedure with 3 (800 mg, 
4-(3-Ethoxycarbonyl-2-isopropylguanidino)-N-(4-(3-ethoxycarbonyl-2-isopropylguanidino)phenyl)benzamide (5c).
Compound 5c was obtained following the general procedure with 3 (800 mg, 1.6 mmol), DIPEA (1.7 mL, 9.8 mmol), EDAC (1.26 g, 6.56 mmol) and isopropylamine (0.57 mL, 6.56 mmol). The product was purified by silica chromatography (10 g SI prepacked column) with CH 2 Cl 2 /EtOAc (100/0→90/10) to yield 5c as white solid (690 mg, 77% 
4-(3-Ethoxycarbonyl-2-methoxyguanidino)-N-(4-(3-ethoxycarbonyl-2-methoxyguanidino)phenyl)benzamide (5d)
Compound 5d was obtained following the general procedure with 3 (500 mg, 95%. LRMS (ES + ) m/z = 544.17 (M+H).
4-(2-Benzyloxy-3-ethoxycarbonylguanidino)-N-(4-(2-benzyloxy-3-ethoxycarbonylguanidino)phenyl)benzamide (5f)
Compound 5f was obtained following the general procedure with 3 (800 mg, 1.6 mmol), DIPEA (1.7 mL, 9.8 mmol), EDAC (1.26 g, 6.56 mmol) and benzyloxyamine (0.76 mL, 6.56 mmol). The product was purified by silica chromatography (5 g SI prepacked column) with EtOAc/MeOH (100/0→90/10) to yield 5f as white solid (875 mg, 80% 
Biology
In vitro antiprotozoal activity
Susceptibility assays against T. b. rhodesiense (strain STIB900) and cytotoxicity assays against rat myoblast L6-cells were performed using an Alamar blue-based assay [24, 36] . Detailed experimental procedures were described in a previous paper [37] . The in vitro antimalarial activity against the chloroquine sensitive strain of P. falciparum NF54 was determined using the [ 3 H]hypoxanthine incorporation assay [25] as previously reported [37] . 4 , and (CG) 4 , respectively. The hydrochloride salts of compounds 7b, 7c, and 8b were dissolved in MES buffer and these stock solutions (C = 5 mM) were used to prepare the different dilutions for the binding experiments.
DNA Immobilization
The DNA hairpins were immobilized independently on three streptavidin-derivatized gold chips (SA chip from Biacore containing 2 flow cells) by injection of a 25 nM hairpin DNA solution with a flow rate of 1 µL/min until a response of about 400 RU was reached. Flow cell 1 was used as reference while flow cell 2 was immobilized with the different DNA hairpins.
Binding Experiments
Typically, a series of different concentrations of compounds 7b, 7c, and 8b was injected 
where r is the moles of bound compound per mole of DNA hairpin duplex, K 1 and K 2 are microscopic binding constants, and C f is the free compound concentration at equilibrium [30, 38] .
